Oral Low-molecular Weight Hyaluronic Acid in the Treatment of Atrophic Vaginitis

AGUNCO Obstetrics and Gynecology Centre

Status and phase: Completed; Phase 4

Conditions: Atrophic Vaginitis

Treatments: Drug: Placebo; Dietary Supplement: Hyaluronic acid

Study type: Interventional

Funder types: Other

Identifiers

NCT02014428

HA-123

Details and patient eligibility

About

To evaluate the effectiveness of low molecular weight hyaluronic acid oral tablets for the treatment of atrophic vaginitis.

Sex: Female

Ages: 45 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• at least 12 months postmenopausal
• mucosal atrophy and the main bothersome related symptoms, such as itching, burning, and dyspareunia.

Trial design

0 participants in 2 patient groups, including a placebo group

Hyaluronic acid

Experimental group

Description:

220 mg hyaluronic acid per tablet (two tablets/day for 10 days, and subsequently one tablet/day for three months)

Treatment:

Dietary Supplement: Hyaluronic acid

Placebo

Placebo Comparator group

Description:

two tablets/day for 10 days, and subsequently one tablet/day for three months

Treatment:

Drug: Placebo